KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$68M

Net Income

-$66M

EPS (Diluted)

$-1.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$65M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$346M

Total Liabilities

$40M

Stockholders' Equity

$307M

Cash & Equivalents

$327M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$68M	-$16M	-314.0%
Net Income	-$66M	-$16M	-311.8%

KNSA Q1 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena